Acquisitions Catapult China Biologic Into Leading Biopharma Outfit; Position It For Global Competition With U.S., EU Players
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The chief executive officer of China Biologic Products Inc. said an aggressive acquisition strategy has helped transform the company into China's leading privately held provider of plasma-based biopharmaceuticals, and that the outfit is aiming to expand its geographical footprint across the globe